Drug Delivery Strategies for Treating Osteoporosis
Yijia Zhang, Anand Dusad and Ke Ren*
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, USA
- *Corresponding Author:
- Ke Ren
Department of Pharmaceutical Sciences
College of Pharmacy Room 3035
986025 Nebraska Medical Center Omaha, USA
E-mail: [email protected]
Received Date: March 24, 2014; Accepted Date: April 23, 2014; Published Date: April 28, 2014
Citation: Zhang Y, Dusad A and Ren K (2014) Drug Delivery Strategies for Treating Osteoporosis. Orthopedic Muscul Sys S2:003. doi:10.4172/2161-0533.S2-003
Copyright: © 2014 Zhang Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Osteoporosis is characterized by a decrease in bone mass and micro architectural deterioration of bone tissue.
Current treatments for osteoporosis are generally associated with many limitations, including low oral bioavailability,
short half time and long-term side effects. Drug delivery systems are developed to reduce off-target side effects,
protect drugs from degradation and control release of the therapeutic agents at the desired sites. This review
presents current research strategies adopted for delivery anti-osteoporosis agents. Oral delivery systems were
developed to facilitate the oral administration of protein drugs. Targeted delivery systems based on bone seeking
agents (such as bisphosphonate) greatly enhanced the distribution of therapeutic agents to bone tissue. Local
administration based on nanoparticles and hydrogels slowly released incorporated drugs and remained a sustained
therapeutic effect in disease site. Though the effects of these systems have been widely approved in animal models,
further researches are needed for a bench-to-bedside transition.